B O O K - American College of Rheumatology

monday
ACR REF Special Session
7:15 - 8:15 am
B406
REF Oscar S. Gluck, MD, Memorial Lectureship -
Osteoimmunology: Crosstalk Between the Immune
and Bone Systems: Biologic and Clinical Implications
c/r
Moderator: Michael J. Maricic, MD; Catalina Pointe
Rheumatology; Tucson, AZ
Speaker: Hiroshi Takayanagi, MD, PhD; Tokyo Medical and
Dental University; Tokyo, Japan
Session Overview:
Many of the molecules and signal pathways controlling the
differentiation and activity of osteoclasts also are involved in
regulating immune cell function and activity. The integration of
knowledge from the fields of immunology and bone cell biology
has reshaped our understanding of the mechanisms involved
in osteoclast-mediated bone resorption and identified new
approaches for treating clinical conditions associated with bone
loss.
Upon completion of this session, participants should be able to:
• describe the signal pathways involved in osteoclast
differentiation and activation
• discuss the common mechanism by which cytokines and
signal pathways regulate immune and bone cells
• describe the potential applications of discoveries in the field
of osteoimmunology for treating clinical disorders associated
with bone loss
ACR State-of-the-Art Lecture
7:30 - 8:30 am
B313
Toll-like Receptors Activation of B cells in
Autoimmune Disease R
Moderator: Jennifer H. Anolik, MD, PhD; University of Rochester;
Rochester, NY
Speaker: Ann Marshak-Rothstein, PhD; University of
Massachusetts Medical School; Worcester, MA
Session Overview:
In recent years it has become clear that toll-like receptors play
a key role in the initiation and perpetuation of autoimmune
responses. Thus, immune complexes such as those found in
autoimmune disease contain ligands for toll-like receptors,
including ribonucleic acid or deoxyribonucleic acid, which can
provide costimulatory signals for autoreactive B cells, promoting
their inappropriate activation and survival. Moreover, toll-like
receptors represent important therapeutic targets. Thus, a stateof-the-art
review of interactions between B cells and toll-like
receptors is timely.
Upon completion of this session, participants should be able to:
• describe the role of toll-like receptors pathways in B cell
activation and contributions to autoimmune disease
• identify how the balance of stimulatory and inhibitory signals
on B cells may define the outcome of toll-like receptors
activation
• provide the rationale for toll-like receptors targeted therapies
in autoimmunity and the potential limitations of such
approaches
ACR Meet the Professor Sessions
7:45 - 9:15 am
Admission to each Meet the Professor session requires a
separate registration and ticket. To verify which session you
registered for, check to make sure the registration code on your
ticket matches the code listed below in parentheses.
B207
Ankylosing Spondylitis: Disease Modification (001)
Speaker: Walter P. Maksymowych, MD; University of Alberta;
Edmonton, AB, Canada
Upon completion of this session, participants should be able to:
• outline what is known about the pathophysiology of disease
modification in spondylarthritis
• review outcomes relevant to the concept of disease
modification in spondylarthritis and assess their relevance to
clinical practice
• review therapeutic issues relevant to the concept of disease
modification
• discuss assessment of disease modification clinical trial
B208
Behçet’s Disease (002)
Speaker: Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul,
Turkey
Upon completion of this session, participants should be able to:
• discuss the epidemiology and diagnostic evaluation of
Behçet’s syndrome
• describe current approaches to the management of patients
with Behçet’s syndrome
B209
Central Nervous System Vasculitis (003)
Speaker: Rula Hajj-Ali, MD; Cleveland Clinic; Cleveland, OH
Upon completion of this session, participants should be able to:
• discuss an approach to the evaluation of a patient referred
with possible central nervous system vasculitis
• review the major entities in the differential diagnosis of
primary angiitis of the central nervous system
• create a consistent therapeutic approach to the treatment of
vasculitis involving the brain and/or spinal cord
B210
Controversies in Sjögren’s Syndrome (004)
Speaker: Frederick B. Vivino, MD; Pennsylvania Presbyterian
Medical Center; Philadelphia, PA
Upon completion of this session, participants should be able to:
• identify major morbidities in Sjögren’s syndrome patients
• discuss current treatment algorithms for dry eyes, dry mouth
and systemic manifestations
• determine strategies to prevent Sjögren’s related
complications
28
2010 Program Book